These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 38519605)

  • 1. XPO1 inhibition displays anti-leukemia efficacy against DNMT3A-mutant acute myeloid leukemia via downregulating glutathione pathway.
    Cai X; Liu Y; Li H; Que Y; Xiao M; Wang Y; Wang X; Li D
    Ann Hematol; 2024 Jul; 103(7):2311-2322. PubMed ID: 38519605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNMT3A R882H mutation drives daunorubicin resistance in acute myeloid leukemia via regulating NRF2/NQO1 pathway.
    Chu X; Zhong L; Dan W; Wang X; Zhang Z; Liu Z; Lu Y; Shao X; Zhou Z; Chen S; Liu B
    Cell Commun Signal; 2022 Oct; 20(1):168. PubMed ID: 36303144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.
    Ranganathan P; Kashyap T; Yu X; Meng X; Lai TH; McNeil B; Bhatnagar B; Shacham S; Kauffman M; Dorrance AM; Blum W; Sampath D; Landesman Y; Garzon R
    Clin Cancer Res; 2016 Dec; 22(24):6142-6152. PubMed ID: 27358488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia.
    Ranganathan P; Yu X; Santhanam R; Hofstetter J; Walker A; Walsh K; Bhatnagar B; Klisovic R; Vasu S; Phelps MA; Devine S; Shacham S; Kauffman M; Marcucci G; Blum W; Garzon R
    Blood; 2015 Apr; 125(17):2689-92. PubMed ID: 25716206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNMT3A R882H mutation promotes acute leukemic cell survival by regulating glycolysis through the NRF2/NQO1 axis.
    Chu X; Zhong L; Dan W; Wang X; Zhang Z; Liu Z; Lu Y; Shao X; Zhou Z; Chen S; Liu B
    Cell Signal; 2023 May; 105():110626. PubMed ID: 36758683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in
    Zhang W; Ly C; Ishizawa J; Mu H; Ruvolo V; Shacham S; Daver N; Andreeff M
    Haematologica; 2018 Oct; 103(10):1642-1653. PubMed ID: 29773601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
    Rau RE; Rodriguez BA; Luo M; Jeong M; Rosen A; Rogers JH; Campbell CT; Daigle SR; Deng L; Song Y; Sweet S; Chevassut T; Andreeff M; Kornblau SM; Li W; Goodell MA
    Blood; 2016 Aug; 128(7):971-81. PubMed ID: 27335278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel impact of the DNMT3A R882H mutation on GSH metabolism in a K562 cell model established by TALENs.
    Yang L; Liu Y; Zhang N; Ding X; Zhang W; Shen K; Huang L; Zhou J; Cui S; Zhu Z; Hu Z; Xiao M
    Oncotarget; 2017 May; 8(18):30395-30409. PubMed ID: 28418922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53.
    Deng M; Zhang M; Xu-Monette ZY; Pham LV; Tzankov A; Visco C; Fang X; Bhagat G; Zhu F; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; Choi WWL; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; van Krieken JH; Piris MA; Winter JN; Hagemeister F; Alinari L; Li Y; Andreeff M; Xu B; Young KH
    J Hematol Oncol; 2020 Nov; 13(1):148. PubMed ID: 33148342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
    Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL
    Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells.
    Etchin J; Berezovskaya A; Conway AS; Galinsky IA; Stone RM; Baloglu E; Senapedis W; Landesman Y; Kauffman M; Shacham S; Wang JC; Look AT
    Leukemia; 2017 Jan; 31(1):143-150. PubMed ID: 27211268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selinexor targeting XPO1 promotes PEG3 nuclear accumulation and suppresses cholangiocarcinoma progression.
    Xiang D; Wang M; Wu H; Chen X; Chen T; Yu D; Xiong L; Xu H; Luo M; Zhang S; Wu L; Yan J
    Cancer Chemother Pharmacol; 2024 Nov; 94(5):669-683. PubMed ID: 39103668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of Selinexor on Proliferation and Apoptosis of Acute Myeloid Leukemia Kasumi-1 Cells].
    Lin LH; Gao SQ; Mei XQ; Lin DY; Chen YF; Lin SD; Zhuang LH; Lin CM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Aug; 32(4):1085-1090. PubMed ID: 39192402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma.
    Garg M; Kanojia D; Mayakonda A; Said JW; Doan NB; Chien W; Ganesan TS; Chuang LS; Venkatachalam N; Baloglu E; Shacham S; Kauffman M; Koeffler HP
    Oncotarget; 2017 Jan; 8(5):7521-7532. PubMed ID: 27893412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1.
    Luedtke DA; Su Y; Liu S; Edwards H; Wang Y; Lin H; Taub JW; Ge Y
    J Cell Mol Med; 2018 Dec; 22(12):6099-6111. PubMed ID: 30596398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia.
    Lin KH; Rutter JC; Xie A; Killarney ST; Vaganay C; Benaksas C; Ling F; Sodaro G; Meslin PA; Bassil CF; Fenouille N; Hoj J; Washart R; Ang HX; Cerda-Smith C; Chaintreuil P; Jacquel A; Auberger P; Forget A; Itzykson R; Lu M; Lin J; Pierobon M; Sheng Z; Li X; Chilkoti A; Owzar K; Rizzieri DA; Pardee TS; Benajiba L; Petricoin E; Puissant A; Wood KC
    Nat Cancer; 2022 Jul; 3(7):837-851. PubMed ID: 35668193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB.
    Ming M; Wu W; Xie B; Sukhanova M; Wang W; Kadri S; Sharma S; Lee J; Shacham S; Landesman Y; Maltsev N; Lu P; Wang YL
    Mol Cancer Ther; 2018 Dec; 17(12):2564-2574. PubMed ID: 30510142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice.
    Etchin J; Montero J; Berezovskaya A; Le BT; Kentsis A; Christie AL; Conway AS; Chen WC; Reed C; Mansour MR; Ng CE; Adamia S; Rodig SJ; Galinsky IA; Stone RM; Klebanov B; Landesman Y; Kauffman M; Shacham S; Kung AL; Wang JC; Letai A; Look AT
    Leukemia; 2016 Jan; 30(1):190-9. PubMed ID: 26202935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
    Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
    Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.
    Shang E; Zhang Y; Shu C; Ishida CT; Bianchetti E; Westhoff MA; Karpel-Massler G; Siegelin MD
    Sci Rep; 2018 Oct; 8(1):15383. PubMed ID: 30337641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.